About eleven
years ago, Crew and Clardy reported the isolation and structure elucidation of
isocyclocitrinol A (shown above), a structurally unique and novel C25 steroid
containing a rearranged A/B ring system (also discussed here). The natural
product was isolated from a terrestrial Penicillium
Citrinum and exhibited modest antibacterial activity. Within the
cyclocitrinol class of rearranged steroids, the usual A/B decalin system is
replaced by a relatively uncommon bicyclo[4.4.1]undecane (highlighted in blue),
a carbocyclic motif that is rarely encountered in Nature. Owing to its
bridgehead olefin, isocyclocitrinol A is an example of a natural product that
violates Bredt’s rule.
The
furanosesquiterpene spiniferin-1 is perhaps the only other example of a natural
product that contains this peculiar bridged bicyclic substructure. And, as
expected, synthetic methods to access a [4.4.1]-bicycle with a bridgehead
double bond are lacking. No member of the cyclocitrinol family has succumbed to
chemical synthesis and racemic spiniferin has only been prepared by two research
groups since its isolation in 1975: 1) James Marshall in the early 1980s and 2)
Weisheng Tian’s laboratory (JOC 2011). Tian’s total synthesis of spiniferin-1
(outlined below) proceeds in only eight steps with an overall efficiency of
nearly 30%. The route features a rearrangement reaction initiated by
polyfluoroalkanosulfonyl fluoride to contruct a strained norcaradiene-type
system, which undergoes subsequent in situ 6p-electrocyclic
ring-expansion to afford spiniferin-1. While elegant and expedient, this method
might not be easily adapted to the preparation of more complex polycyclic
molecular architectures (e.g. isocyclocitrinol A). Two approaches to the
stereocontrolled chemical synthesis of highly elaborated cyclocitrinol advanced
precursors have been described in the literature. The first of those is a
semisynthetic strategy related to the natural product’s biosynthetic origin
(see below), disclosed by the laboratory of Hans-Günther Schmalz in 2007. Schmalz’s
captivating synthetic entry towards the cyclocitrinols will be the subject of
this post.
It is first
instructive to consider a plausible biosynthetic pathway (shown below) leading
to the cyclocitrinols, advanced by Rodrigues-Filho and co-workers in 2005.
The authors postulate that the angular C19 methyl group of ergosterol could
undergo nucleophilic attack by the steroid A/B ring junction position C5 to produce
an intermediary cyclopropane structure. Rupture of this ring system by
deprotonation at C1 then generates the unique [4.4.1]-bicycle. In addition, oxidative
fragmentation of the ergosterol C17 side chain with elimination of acetone also
leads to the cyclocitrinols. Given this very reasonable biosynthetic
hypothesis, a semisynthetic approach to the cyclocitrinols involving
ring-expansion of an appropriate steroidal system containing an
electronically-tuned cyclopropane, fused across the A/B junction, should
constitute a viable tactic for assembly of the cyclocitrinol core. Schmalz’s
group executed this chemistry by developing a samarium iodide-mediated
reductive cyclopropane fragmentation reaction that was successfully applied to
a highly elaborated substrate, culminating in the first stereocontrolled
construction of the cyclocitrinol core structure.
In order to
demonstrate the critical reductive cyclopropane cleavage step, a steroidal cyclopropyltrione
intermediate was required. The synthesis of this substrate was achieved by
controlled, site-selective oxidative modification of commercially available
dehydroepiandrosterone. The corresponding C1-O-acetate congener was first prepared by a six-step synthetic sequence. The
C19 angular methyl group is then functionalized by converting the D5,6 olefinic intermediate to its bromohydrin
derivative. This provides the substrate for subsequent implementation of
Meystre's hypoiodite C-H functionalization reaction (discussed here). Reduction
of the resultant lactol acetate product with concomitant elimination then gave the
19-hydroxy androsterone, equipped with a pre-installed leaving group (acetate) at
C1. This intermediate was converted into a cyclopropane derivative via the
intermediacy of its corresponding mesylate. Finally, three additional steps
involving 1) regioselective methanolysis 2) Dess-Martin oxidation and 3)
elimination of the axial C1 acetoxy group secured the requisite enedione/triketone
substrate for reductive cyclopropane fragmentation.
In the event,
when the cyclopropyltrione substrate was added to samarium iodide in
tetrahydrofuran, cyclopropane cleavage proceeded instantaneously (mechanistic
pathway depicted below) to forge the bicyclo[4.4.1]undecane motif of
cyclocitrinol A. The 15-step approach to the core structure proceeds in around 2% overall yield. The advanced precursor synthesized by Schmalz and co-workers
may be suitable for elaboration to the cyclocitrinols provided that the
reactivity of carbonyl functionality at C3 and C17 can be reasonably distinguished.
Regioselective functionalization at C17 is required for side chain installation
and the C3 ketone must, at some point, be reduced to a carbinol.
James
Leighton’s group at Columbia University has very recently disclosed an
alternate de novo synthesis of the
cyclocitrinol core skeleton. The Columbia route will be examined and contrasted
with the clever pioneering entry of Schmalz’s lab in a forthcoming post.